Chitosan-Orientin Nanoparticles Attenuate Hypoxia-Induced Pulmonary Inflammation in Rats

Background: Hypoxia triggers pulmonary inflammation and oxidative stress, leading to endothelial dysfunction, apoptosis and lung injury. Although the flavonoid orientin exhibits potent antioxidant and anti-inflammatory properties, its pharmacokinetic behavior remains incompletely characterized. Nanoparticle-based delivery systems may enhance efficacy. This study investigated whether Orientin delivered via chitosan nanoparticles (CNP-orientin) protects against hypoxia-induced pulmonary inflammation, oxidative stress, and tissue injury in rats. Methods: A total of 48 female Sprague-Dawley rats were randomized into four normoxic and four hypoxic groups (n = 6 per group). Rats in the hypoxic groups were exposed to intermittent hypoxia (7% O₂, 8 h/day for 7 days). Hypoxic rats were allocated to experimental groups, including an untreated hypoxia group and groups receiving orientin alone, chitosan nanoparticles alone or orientin-loaded chitosan nanoparticles (CNP-orientin), while normoxic rats served as controls. Hypoxic exposure was conducted using a controlled glove box system. At the end of the protocol, blood samples were collected for serum inflammatory marker analysis, and lung tissues were harvested to assess oxidative stress parameters, hypoxia- and inflammation-related signaling pathways, apoptosis-related gene expression, and histopathological lung injury and fibrosis. Results: Intermittent hypoxia significantly increased pulmonary HIF-1α and iNOS expression, oxidative stress markers (increased malondialdehyde and decreased superoxide dismutase and glutathione), pro-inflammatory cytokines (TNF-α, IL-1β), apoptotic signaling and histopathological lung injury compared with normoxic controls (p < 0.05). Treatment with orientin or chitosan nanoparticles alone attenuated hypoxia-associated biochemical and molecular alterations compared to untreated hypoxic rats (p < 0.05). Notably, CNP-orientin treatment significantly attenuated multiple oxidative stress, inflammatory, and apoptosis-related alterations compared with untreated hypoxic rats (p < 0.05). These protective effects were observed despite the substantially lower orientin-equivalent dose in the CNP-orientin formulation compared with free orientin. NF-κB and TNF-α expression, caspase-3 levels, antioxidant markers, and Bcl-2 expression differed significantly among hypoxic groups (p < 0.05). Histopathological lung injury and Modified Ashcroft fibrosis scores were significantly lower in the CNP-orientin group than in the untreated hypoxic group (p < 0.01 and p < 0.001, respectively). Conclusions: Orientin-loaded chitosan nanoparticles effectively mitigate hypoxia-induced pulmonary inflammation, oxidative stress, apoptosis and fibrotic injury. These findings identify CNP-orientin as a promising nanotherapeutic strategy for hypoxia-associated lung diseases and support further translational investigations.